Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Renal Cell Carcinoma Clinical Trial

Official title:

Safety and Efficacy of Neoadjuvant Lenvatinib and Pembrolizumab in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05319015
• Other study ID #: STU-2021-1240
• Status: Recruiting
• Phase: Phase 2
• Start date: January 6, 2023
• Est. completion date: August 2025

Study information

• Verified date: February 2024
• Source: University of Texas Southwestern Medical Center
• Contact: Donna Mitchell
• Phone: 214-645-8787
• Email: donna.mitchell[@]utsouthwestern.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male/female participants who are at least 18 years of age

• Have histologically confirmed cT3-4,N0-1,M0-1 (clinical stage III-IV) diagnosis of renal cell carcinoma (any subtype) with level II-IV inferior vena cava tumor thrombus

• The primary tumor and thrombus may be assessed to be resectable or unresectable at the time of enrollment

• Male participants: A male participant must agree to use a protocol-approved contraception during the 120 day neoadjuvant treatment period and for at least 90 days after the last dose of study treatment and refrain from donating sperm during this period.

• Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

1. Not a woman of childbearing potential (WOCBP) OR

2. A WOCBP who agrees to follow the protocol-approved contraceptive guidance during the treatment period and for at least 30 days after the last dose of study treatment.

• The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.

• Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

• Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.

• Have adequate organ function as defined in the following table. Specimens must be collected within 10 days prior to the start of study intervention.

• Absolute neutrophil count (ANC): =1500/µL

• Platelets: =100 000/µL

• Hemoglobin: =9.0 g/dL or = 5.6 mmol/La

• Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl): =1.5 × ULN OR =30 mL/min for participant with creatinine levels >1.5 × institutional ULN

• Total bilirubin: =1.5 ×ULN OR direct bilirubin = ULN for participants with total bilirubin levels >1.5 × ULN

• AST (SGOT) and ALT (SGPT): =2.5 × ULN (=5 × ULN for participants with liver metastases)

• International normalized ratio (INR) OR prothrombin time (PT) OR Activated partial thromboplastin time (aPTT): =1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

• ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.

• Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.

• Creatinine clearance (CrCl) should be calculated per institutional standard.

• Note: This includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies.

Exclusion Criteria:

• A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).

• Has received prior systemic anti-cancer therapy including investigational agents prior to allocation.

• Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease.

• Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccines are permitted provided they are not live attenuated vaccines.

• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.

• Has a known additional malignancy that is progressing or has required active treatment within the past year. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical cancer, bladder in situ) that have undergone potentially curative therapy are not excluded.

• Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.

• Has more than three different sites of metastatic renal cell carcinoma.

• Has severe hypersensitivity (=Grade 3) to pembrolizumab and lenvatinib and/or any of its excipients.

• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.

• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.

• Has an active infection requiring systemic therapy.

• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.

• Has had an allogenic tissue/solid organ transplant.

• Has prolongation of QTcF interval to >480 ms.

• Has a left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO)

• Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability. Note: Medically controlled arrhythmia would be permitted

• Has urine protein =1 g/24 hours. Note: Participants with proteinuria =2+>1+ (=100 mg/dL) on urine dipstick testing (urinalysis) will undergo 24-hour urine collection for quantitative assessment of proteinuria.

• Uncontrolled blood pressure (Systolic BP>140 mmHg or diastolic BP >90 mmHg) in spite of an optimized regimen of antihypertensive medication.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Renal Cell Carcinoma
• Thrombosis

Intervention

Drug:
• Neoadjuvant Lenvatinib
20 mg PO daily for 12 weeks prior to surgery
• Neoadjuvant Pembrolizumab
200 mg IV every 3 weeks for 4 doses prior to surgery

Procedure:
• Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
Resection of locally advanced RCC with IVC tumor thrombus

Drug:
• Adjuvant Pembrolizumab
200 mg IV every 3 weeks for up to 13 doses after surgery

Locations

Country	Name	City	State
United States	University of Texas Southwestern Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Outcomes	Identify metabolic signatures in plasma that are noninvasive predictors of therapy response and identify metabolic alterations following neoadjuvant therapy in patients who do and do not respond.	24 weeks
Primary	Disease Control Rate	Evaluation of changes in size of primary tumor and size and level of IVC tumor thrombus on imaging due to neoadjuvant therapy prior to surgery.	12 weeks
Primary	Local and Metastatic Progression Rate	Evaluation of local or metastatic progression on imaging prior to surgery following neoadjuvant therapy.	12 weeks
Primary	90 Day Post-Operative Complications	Assessment of 90 day post-operative safety and morbidity of neoadjuvant therapy by evaluating the incidence of 90 day post-operative grade 3-5 adverse events.	13 weeks
Secondary	Estimated blood loss	Estimated blood loss in mL during surgery	1 week
Secondary	Operative time	Operative time in minutes of surgery, length of stay, and intra-operative and post-operative complications	1 week
Secondary	Length of stay	Length of stay of hospital stay for surgery in days, and intra-operative and post-operative complications	1 week
Secondary	Intra-operative complications	Complications that occur during surgery	1 week
Secondary	Post-operative complications	Complications that occur in the post-operative period	12 weeks
Secondary	Survival Outcomes	Evaluation of post-operative survival outcomes including recurrence-free survival and overall survival.	3 years